On the morning of January 21, 2021, the 13th Healthy China Forum Annual Series List hosted by the People's Daily Health Client and People's Daily Health Times was released on the People's Daily Health Client. The forum produced ten major figures in the pharmaceutical industry (domestic and foreign), top ten health industry figures, top ten new drugs (international and domestic), top ten Internet + medical service innovation hospitals, top ten health care projects, and top ten keywords Waiting for the seven series list. Wu Yifang, Chairman and CEO of Fosun Pharma, won the top ten pharmaceutical industry figures (domestic), and Hanquyou, the first Chinese-European dual batch of domestic monoclonal antibody biosimilars independently developed by Fuhong Hanli, was awarded the top ten new drugs ( domestic).

Wu Yifang joined Fosun Pharma in April 2004, and served as President and CEO of Fosun Pharma from 2016 to October 2020, and Chairman and CEO of Fosun Pharma from October 2020 until now. Wu Yifang also served as a representative of the Jiangsu Provincial People's Congress, an executive director of the China Pharmaceutical Regulatory and Research Association, a vice president of the China Medical News Information Association, a vice president of the China Pharmaceutical Enterprise Management Association, a vice president of the China Chemical Pharmaceutical Industry Association, and a vice president of the China Non-Prescription Drug Association. President. In 2020, Wu Yifang won the 2020 Pharmaceutical Industry Pioneer of the Year and the 3rd Putuo District Chief Quality Award and other honors.